Bristol-Myers Squibb Company vs Pfizer, Inc. — Stock Comparison
Bristol-Myers Squibb Company (BMY) and Pfizer, Inc. (PFE) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Bristol-Myers Squibb Company clearly outscores Pfizer, Inc. on Q·Score (7.2 vs 5.7 out of 10), led by Quality (8.8 vs 5) and Growth (8.1 vs 5.9). Pfizer, Inc. scores higher on Health, reflecting stronger balance sheet strength. Analyst consensus targets imply greater upside for BMY (+6.0%) than for PFE (-1.8%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
High-quality business with 47% return on equity and 19% profit margins.
⚠ analyst sentiment is cautious.
Consistently beats earnings estimates (4/4 quarters).
⚠ cautious analyst consensus — few Buy ratings.
Analyst Consensus
Fundamentals
Frequently Asked Questions
BMY vs PFE: which stock scores better overall?
Based on Q·Score, Bristol-Myers Squibb Company (BMY) scores 7.2/10 versus Pfizer, Inc. (PFE) at 5.7/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: BMY or PFE?
Bristol-Myers Squibb Company (BMY) scores higher on Growth (8.1/10 vs 5.9/10). Bristol-Myers Squibb Company reports revenue growth (5.7% YoY) while Pfizer, Inc. reports (2.6% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is BMY or PFE more attractively valued?
Bristol-Myers Squibb Company (BMY) scores higher on Valuation (6.7/10 vs 5.9/10). BMY trades at 9.3× P/E versus PFE at 10.3×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about BMY vs PFE?
There are 24 analysts covering BMY with a consensus price target of $65.25, and 26 analysts covering PFE with a consensus target of $29.26. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: BMY or PFE?
Bristol-Myers Squibb Company (BMY) scores higher on Quality (8.8/10 vs 5/10). Net profit margin: BMY at 18.9%, PFE at 6.8%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: BMY or PFE?
Pfizer, Inc. (PFE) scores higher on Financial Health (7/10 vs 6.1/10). Market beta: BMY at 0.18, PFE at 0.28. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of BMY and PFE?
Bristol-Myers Squibb Company (BMY) has a market capitalisation of $125.7B, while Pfizer, Inc. (PFE) has a market cap of $169.9B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do BMY or PFE pay dividends?
BMY pays a dividend yield of 4.09%, while PFE pays a dividend yield of 5.77%. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →